Abstract
The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.
Original language | English |
---|---|
Pages (from-to) | 242-250 |
Number of pages | 9 |
Journal | Therapeutic Advances in Respiratory Disease |
Volume | 9 |
Issue number | 5 |
DOIs | |
Publication status | Published - Oct 29 2015 |
Keywords
- AZD9291
- CO-1686
- epidermal growth factor receptor activating mutations
- HM61713
- non-small cell lung cancer
- T790M mutation
- tyrosine kinase inhibitors
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Pharmacology (medical)